Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Why Dentists Should Be Concerned about Superbugs and Antibiotic Resistance

On this episode of HealthFirst Talks, host Dr. Don Cohen, Chief Clinical Officer, HealthFirst, talked with a panel about the concern of superbugs and antibiotic resistance in dentistry. The panel included Dr. Fiona Collins, General Dentist and infection control expert, Dr. Scott Cohen, family physician and clinical informaticist, Dr. Heather Ferrarese, a clinical pharmacist with…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from HealthFirst on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

On this episode of HealthFirst Talks, host Dr. Don Cohen, Chief Clinical Officer, HealthFirst, talked with a panel about the concern of superbugs and antibiotic resistance in dentistry. The panel included Dr. Fiona Collins, General Dentist and infection control expert, Dr. Scott Cohen, family physician and clinical informaticist, Dr. Heather Ferrarese, a clinical pharmacist with a concentration in community pharmacy, and Dr. Stanley Malamed, a dentist anesthesiologist.

This panel discussion was presented at the 2021 OSAP Virtual Conference.

While this panel is about the concern of antibiotic resistance, it’s important to note all the good that they have done, according to Ferrarese. She elaborated that Penicillin was discovered in 1928 by Alexander Fleming, and, since then, antibiotics have become the cornerstone of modern medicine. Along with public sanitation and immunization, antibiotics have significantly contributed to the control of infectious diseases, including doubling the life span in developing countries over the past two centuries. 

However, this doesn’t mean they’re without they’re challenges and negative impacts.

“Antibiotics can cause adverse drug reactions,” Collins said. “One of the particularly worrying ones is actually gastrointestinal infections, in particular C. difficile.”

These bacteria mainly affect older patients in long-term care facilities or hospitals and usually occur after administering antibiotics. It causes a range of symptoms, ranging from diarrhea to life-threatening inflammation of the colon.

The group also dug into how to identify the key risks and concerns with superbugs, offered insight into how to understand the frequency in which antibiotic prescriptions are written and how often they are overprescribed, and highlighted recommendations from the ADA, AHA, and AAOS. Listen to hear more of the group’s chat.

While low-intensity options could be safer, it’s important to understand your space, the specific device and solution you’re looking into, and how to make a space as safe as possible without putting inhabitants in danger.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

HealthFirst

Part of this channel

HealthFirst

Practice-ready solutions for dental and medical offices nationwide.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

CMS Sets $90-$420 Per-Patient Payments for Chronic Care Tech

CMS Sets $90-$420 Per-Patient Payments for Chronic Care Tech

CMS's ACCESS payment model, fully active as of July 2026, pays companies $90 to $420 per Medicare beneficiary per year for technology-supported chronic care tied to outcomes, according to HFMA. The model also requires participants to connect through CMS-designated interoperability networks, and more tech companies than traditional providers have signed on so far.

  • 01CMS ACCESS model provides annual payments of $90 to $420 per Medicare beneficiary for chronic care supported by technology.
  • 02Payments in the ACCESS model range from $90 to $420 per beneficiary per year depending on whether specified outcome targets are met.
  • 03The initiative aims to promote the integration of technology in chronic care management.

Sep 10, 2026

Google’s AlphaGenome Atlas puts billions of DNA variants in reach

Google’s AlphaGenome Atlas puts billions of DNA variants in reach

AlphaGenome Atlas gives researchers predicted molecular effects for possible DNA changes across the human genome, helping teams prioritize variants for experimental follow-up.

  • 01The Atlas covers roughly nine billion possible single-letter DNA substitutions, according to The Verge.
  • 02Predictions can prioritize research questions but do not establish clinical findings.
  • 03The useful implementation pattern is prediction, study-specific evidence, then validation.

Sep 9, 2026

OpenAI put 10,000 AI agents on Navier–Stokes. Healthcare R&D should pay attention

OpenAI put 10,000 AI agents on Navier–Stokes. Healthcare R&D should pay attention

OpenAI says roughly 10,000 AI agents produced a proposed Navier–Stokes solution in 88 hours, followed by Lean verification. For healthcare and life sciences, the immediate signal is a research workflow built around parallel agents, code execution, provenance and formal checking—not a ready-made clinical simulator.

  • 01OpenAI's result is a proposed proof under review, not a new clinical simulation product.
  • 02The near-term B2B signal is a coordinated research stack combining agents, code and formal verification.
  • 03Healthcare buyers should evaluate provenance, reproducibility, security and cost per validated result.

Sep 9, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512